menu
    • menu

    Company profile for Chiesi Group

    NEW Drugs in Dev: 45
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. With a turnover of €1,768 millions we are among the top 50 pharmaceutical companies in the world. Our production sites are in Parma, Italy, Blois (France) and ...
    We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. With a turnover of €1,768 millions we are among the top 50 pharmaceutical companies in the world. Our production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil). Its R&D centres in Parma (Italy), Paris (France), Cary (USA), Chippenham and Oxford (UK) and Lidingö (Sweden) part of the acquisition of protein therapeutics biotech Zymenex in 2013.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Chiesi GroupItaly Flag
    Country
    Country
    Italy
    Address
    Address
    26/A, Via Palermo (Main entrance: 1, Via Giacomo Chiesi) 43122 Parma
    Telephone
    Telephone
    +39 0521 2791
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.chiesi.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.chiesi.com%2Fen%2Fabout-us%2F
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chiesi Farmaceutici’s Trimbow Receives Approval in US
    Chiesi Farmaceutici’s Trimbow Receives Approval in US

    14 May 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219622

    FDA
    14 May 2026
    Share Share
    Debra Hussain Joins Chiesi USA as VP of U.S. CARE
    Debra Hussain Joins Chiesi USA as VP of U.S. CARE

    12 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/12/3292757/0/en/debra-hussain-joins-chiesi-usa-as-vice-president-and-business-unit-leader-u-s-care.html

    GLOBENEWSWIRE
    12 May 2026
    Share Share
    Chiesi Snaps Up Kalvista For $1.9B, Betting Big On Rare Disease
    Chiesi Snaps Up Kalvista For $1.9B, Betting Big On Rare Disease

    30 Apr 2026

    // BIOSPACE

    https://www.biospace.com/business/chiesi-snaps-up-kalvista-for-1-9b-betting-big-on-rare-disease-med-ekterly

    BIOSPACE
    30 Apr 2026
    Share Share
    Chiesi Unveils Robust FY2025 Results And Leadership Change
    Chiesi Unveils Robust FY2025 Results And Leadership Change

    23 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7205609

    FIRSTWORD PHARMA
    23 Apr 2026
    Share Share
    Veld Pharma, Chiesi Expand Rare Disease Therapy Access in Africa
    Veld Pharma, Chiesi Expand Rare Disease Therapy Access in Africa

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272460/0/en/Veld-Pharmaceuticals-GmbH-Announces-Collaboration-with-Chiesi-Farmaceutici-S-p-A-to-Expand-Access-to-Rare-Disease-Therapies-Across-Africa.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    Chiesi, Bespak Partner For Carbon Minimal Inhaler Production
    Chiesi, Bespak Partner For Carbon Minimal Inhaler Production

    11 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-11/chiesi-and-bespak-partner-to-advance-carbon-minimal-inhaler-production-with-uk-manufacturing-site-1

    PHARMIWEB
    11 Mar 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search